Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.

Risultato della ricerca: Article

23 Citazioni (Scopus)

Abstract

The obesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor (VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated receptor (PPAR) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and VEGF in breast cancer cells. In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and GW1929 elevated the expression of leptin and VEGF mRNA and protein, and increased cell viability and migration. These effects coincided with increased recruitment of PPAR to the proximal leptin promoter and decreased association of a transcriptional factor Sp1 with this DNA region.
Lingua originaleEnglish
pagine (da-a)1368-1374
Numero di pagine7
RivistaJournal of Cellular Physiology
Volume228
Stato di pubblicazionePublished - 2013

Fingerprint

PPAR gamma
Leptin
Vascular Endothelial Growth Factor A
Cells
Breast Neoplasms
Peroxisome Proliferator-Activated Receptors
Obesity
Leptin Receptors
Medical problems
Type 2 Diabetes Mellitus
Cell Movement
Tumors
Cell Survival
Proteins
Hormones
Ligands
Messenger RNA
DNA
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Cell Biology
  • Clinical Biochemistry
  • Physiology

Cita questo

@article{28d1916b39774c6bafe18097b9c712dd,
title = "Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.",
abstract = "The obesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor (VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated receptor (PPAR) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and VEGF in breast cancer cells. In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and GW1929 elevated the expression of leptin and VEGF mRNA and protein, and increased cell viability and migration. These effects coincided with increased recruitment of PPAR to the proximal leptin promoter and decreased association of a transcriptional factor Sp1 with this DNA region.",
author = "Antonio Russo and Viviana Bazan and Giuseppe Cicero and {Lo Re}, Giuseppe and Marianna Terrasi and Daniele Fanale and Corsini, {Lidia Rita} and Valeria Amodeo and Lavinia Insalaco and Stefano Caruso",
year = "2013",
language = "English",
volume = "228",
pages = "1368--1374",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.

AU - Russo, Antonio

AU - Bazan, Viviana

AU - Cicero, Giuseppe

AU - Lo Re, Giuseppe

AU - Terrasi, Marianna

AU - Fanale, Daniele

AU - Corsini, Lidia Rita

AU - Amodeo, Valeria

AU - Insalaco, Lavinia

AU - Caruso, Stefano

PY - 2013

Y1 - 2013

N2 - The obesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor (VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated receptor (PPAR) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and VEGF in breast cancer cells. In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and GW1929 elevated the expression of leptin and VEGF mRNA and protein, and increased cell viability and migration. These effects coincided with increased recruitment of PPAR to the proximal leptin promoter and decreased association of a transcriptional factor Sp1 with this DNA region.

AB - The obesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor (VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated receptor (PPAR) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and VEGF in breast cancer cells. In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and GW1929 elevated the expression of leptin and VEGF mRNA and protein, and increased cell viability and migration. These effects coincided with increased recruitment of PPAR to the proximal leptin promoter and decreased association of a transcriptional factor Sp1 with this DNA region.

UR - http://hdl.handle.net/10447/74733

M3 - Article

VL - 228

SP - 1368

EP - 1374

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

ER -